UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Thrombosis: a major contributor to the global disease burden

Journal of thrombosis and haemostasis, 2014-10, Vol.12 (10), p.1580-1590

2014

Link zum Volltext

Verfügbarkeit prüfen

Thrombosis: a major contributor to global disease burden

Arteriosclerosis, thrombosis, and vascular biology, 2014-11, Vol.34 (11), p.2363

2014

Link zum Volltext

Verfügbarkeit prüfen

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Journal of thrombosis and haemostasis, 2015-12, Vol.13 (12), p.2187-2191

2015

Link zum Volltext

Verfügbarkeit prüfen

Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

Journal of thrombosis and haemostasis, 2013-02, Vol.11 (2), p.245-252

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Journal of thrombosis and haemostasis, 2014-09, Vol.12 (9), p.1428-1436

2014

Link zum Volltext

Verfügbarkeit prüfen

Global public awareness of venous thromboembolism

Journal of thrombosis and haemostasis, 2015-08, Vol.13 (8), p.1365-1371

2015

Link zum Volltext

Verfügbarkeit prüfen

Thrombosis: A major contributor to global disease burden

Thrombosis research, 2014-11, Vol.134 (5), p.931-938

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents

Journal of thrombosis and haemostasis, 2014-11, Vol.12 (11), p.1810-1815

2014

Link zum Volltext

Verfügbarkeit prüfen

Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells

Journal of thrombosis and haemostasis, 2016-02, Vol.14 (2), p.366-374

2016

Link zum Volltext

Verfügbarkeit prüfen

D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment

Thrombosis research, 2016-10, Vol.146, p.119-125

2016

Link zum Volltext

Verfügbarkeit prüfen

COMPARISON OF THE EFFECT OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS AND WARFARIN ON MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION

Canadian journal of cardiology, 2015-10, Vol.31 (10), p.S199-S199

2015

Link zum Volltext

Verfügbarkeit prüfen

4 Initial Experience With Idarucizumab in Dabigatran-Treated Patients Presenting With Acute Gastrointestinal Hemorrhage: Interim Results from the RE-VERSE AD Study

Annals of emergency medicine, 2015-10, Vol.66 (4), p.S2-S3

2015

Link zum Volltext

Verfügbarkeit prüfen

262 Initial Experience With Idarucizumab in Dabigatran-Treated Patients Presenting With Acute Traumatic Injuries: Interim Results From the RE-VERSE AD Study

Annals of emergency medicine, 2015-10, Vol.66 (4), p.S94-S94

2015

Link zum Volltext

Verfügbarkeit prüfen

Medical device‐induced thrombosis: what causes it and how can we prevent it?

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (S1), p.S72-S81

2015

Link zum Volltext

Verfügbarkeit prüfen

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2016-03, Vol.14 (3), p.623-627

2016

Link zum Volltext

Verfügbarkeit prüfen

ANALYSIS OF THE BLEEDING AND THROMBOEMBOLIC RISK WITH CONCOMITANT USE OF ANTIPLATELET TREATMENT IN THE AMPLIFY TRIAL

Canadian journal of cardiology, 2014-10, Vol.30 (10), p.S272-S272

2014

Link zum Volltext

Verfügbarkeit prüfen

APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL

Canadian journal of cardiology, 2014-10, Vol.30 (10), p.S278-S278

2014

Link zum Volltext

Verfügbarkeit prüfen

Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke

Journal of thrombosis and haemostasis, 2018-10, Vol.16 (10), p.1932-1940

2018

Link zum Volltext

Verfügbarkeit prüfen

504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial

Canadian journal of cardiology, 2012-09, Vol.28 (5), p.S285-S285

2012

Link zum Volltext

Verfügbarkeit prüfen

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study

Thrombosis research, 2020-01, Vol.185, p.13-19

2020

Link zum Volltext

Verfügbarkeit prüfen

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

Journal of thrombosis and haemostasis, 2018-01, Vol.16 (1), p.54-64

2018

Link zum Volltext

Verfügbarkeit prüfen

Factor Xa or thrombin: Is thrombin a better target?

Journal of thrombosis and haemostasis, 2007-07, Vol.5, p.65-67

WEITZ, J. I.

2007

Link zum Volltext

Verfügbarkeit prüfen

Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis

Journal of thrombosis and haemostasis, 2018-03, Vol.16 (3), p.413-417

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations

Journal of thrombosis and haemostasis, 2017-12, Vol.15 (12), p.2377-2387

2017

Link zum Volltext

Verfügbarkeit prüfen

Real‐world variability in dabigatran levels in patients with atrial fibrillation

Journal of thrombosis and haemostasis, 2015-03, Vol.13 (3), p.353-359

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(59)
Buchkapitel
(1)

Sprache

Englisch
(60)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(34)
Cardiovascular System & Cardiology
(32)
Hematology
(30)
Peripheral Vascular Disease
(30)
Humans
(28)
Male
(17)
Female
(14)
Middle Aged
(12)
Anticoagulants
(10)
Aged
(9)
Blood Coagulation - Drug Effects
(9)
Time Factors
(9)
Risk Factors
(8)
Thrombosis
(8)
Treatment Outcome
(8)
Animals
(7)
Adult
(6)
Anticoagulants - Administration & Dosage
(6)
Drug Administration Schedule
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Thrombosis: a major contributor to the global disease burden

Thrombosis: a major contributor to global disease burden

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Global public awareness of venous thromboembolism

Thrombosis: A major contributor to global disease burden

Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents

Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells

D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment

COMPARISON OF THE EFFECT OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS AND WARFARIN ON MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION

4 Initial Experience With Idarucizumab in Dabigatran-Treated Patients Presenting With Acute Gastrointestinal Hemorrhage: Interim Results from the RE-VERSE AD Study

262 Initial Experience With Idarucizumab in Dabigatran-Treated Patients Presenting With Acute Traumatic Injuries: Interim Results From the RE-VERSE AD Study

Medical device‐induced thrombosis: what causes it and how can we prevent it?

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

ANALYSIS OF THE BLEEDING AND THROMBOEMBOLIC RISK WITH CONCOMITANT USE OF ANTIPLATELET TREATMENT IN THE AMPLIFY TRIAL

APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL

Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke

504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

Factor Xa or thrombin: Is thrombin a better target?

Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis

Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations

Real‐world variability in dabigatran levels in patients with atrial fibrillation

Suchergebnisse filtern